Insider Selling: Reata Pharmaceuticals Inc (RETA) CFO Sells 3,000 Shares of Stock

Share on StockTwits

Reata Pharmaceuticals Inc (NASDAQ:RETA) CFO Jason Douglas Wilson sold 3,000 shares of the stock in a transaction dated Tuesday, February 5th. The shares were sold at an average price of $80.00, for a total value of $240,000.00. Following the completion of the sale, the chief financial officer now directly owns 3,000 shares in the company, valued at approximately $240,000. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Jason Douglas Wilson also recently made the following trade(s):

  • On Friday, February 1st, Jason Douglas Wilson sold 7,000 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $80.00, for a total value of $560,000.00.
  • On Tuesday, January 15th, Jason Douglas Wilson sold 4,000 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $71.15, for a total value of $284,600.00.
  • On Monday, January 7th, Jason Douglas Wilson sold 20,000 shares of Reata Pharmaceuticals stock. The stock was sold at an average price of $72.04, for a total value of $1,440,800.00.

Shares of NASDAQ RETA traded down $1.79 during midday trading on Thursday, hitting $79.28. 16,604 shares of the company’s stock were exchanged, compared to its average volume of 177,478. The company has a debt-to-equity ratio of 2.10, a quick ratio of 6.04 and a current ratio of 6.04. Reata Pharmaceuticals Inc has a twelve month low of $19.31 and a twelve month high of $99.50. The firm has a market capitalization of $2.41 billion, a PE ratio of -39.84 and a beta of 3.15.

Reata Pharmaceuticals (NASDAQ:RETA) last issued its earnings results on Wednesday, November 7th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.28). The firm had revenue of $5.18 million during the quarter, compared to analyst estimates of $9.50 million. On average, sell-side analysts forecast that Reata Pharmaceuticals Inc will post -3.08 earnings per share for the current fiscal year.

Several brokerages have recently weighed in on RETA. Cantor Fitzgerald set a $100.00 target price on Reata Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, November 7th. BidaskClub lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 15th. ValuEngine raised Reata Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday. Finally, Zacks Investment Research raised Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 10th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $100.33.

Hedge funds and other institutional investors have recently modified their holdings of the company. TD Asset Management Inc. grew its stake in Reata Pharmaceuticals by 2.0% during the 4th quarter. TD Asset Management Inc. now owns 15,613 shares of the company’s stock worth $876,000 after buying an additional 300 shares during the last quarter. Meeder Asset Management Inc. grew its stake in Reata Pharmaceuticals by 60.9% during the 4th quarter. Meeder Asset Management Inc. now owns 1,469 shares of the company’s stock worth $82,000 after buying an additional 556 shares during the last quarter. Legal & General Group Plc grew its stake in Reata Pharmaceuticals by 24.2% during the 3rd quarter. Legal & General Group Plc now owns 3,062 shares of the company’s stock worth $250,000 after buying an additional 597 shares during the last quarter. State Board of Administration of Florida Retirement System grew its stake in Reata Pharmaceuticals by 9.9% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 7,612 shares of the company’s stock worth $427,000 after buying an additional 686 shares during the last quarter. Finally, TIAA CREF Investment Management LLC grew its stake in Reata Pharmaceuticals by 3.1% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 31,399 shares of the company’s stock worth $2,567,000 after buying an additional 956 shares during the last quarter. 52.80% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Reata Pharmaceuticals Inc (RETA) CFO Sells 3,000 Shares of Stock” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4132861/insider-selling-reata-pharmaceuticals-inc-reta-cfo-sells-3000-shares-of-stock.html.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.

Read More: Book Value Per Share – BVPS

Insider Buying and Selling by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Envion  One Day Volume Tops $1,493.00
Envion One Day Volume Tops $1,493.00
Mercury Reaches 24-Hour Volume of $202,462.00
Mercury Reaches 24-Hour Volume of $202,462.00
Shoe Carnival, Inc.  Given Average Rating of “Buy” by Analysts
Shoe Carnival, Inc. Given Average Rating of “Buy” by Analysts
Analysts Expect Neptune Wellness Solutions Inc  to Announce $0.00 EPS
Analysts Expect Neptune Wellness Solutions Inc to Announce $0.00 EPS
CyrusOne  Posts Quarterly  Earnings Results, Beats Expectations By $0.04 EPS
CyrusOne Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS
William E. Rote Sells 1,250 Shares of Retrophin Inc  Stock
William E. Rote Sells 1,250 Shares of Retrophin Inc Stock


Leave a Reply

© 2006-2019 Ticker Report